Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-15

FDA Approved: RADICAVA — Supplemental Application (Shionogi Inc.)

View source ↗

Summary

The FDA approved a supplemental application for RADICAVA (edaravone) from Shionogi Inc., marking an additional regulatory approval for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Radicava (edaravone)

Snippet

SUPPL AP for RADICAVA (EDARAVONE)